Drug Trial Radar · NCT07226999
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy and With Tarlatamab, Alone or With Chemotherapy, in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
550
Planned (sponsor's estimate)
Start
Dec 9, 2025
Primary completion
Jun 14, 2030
Study completion Mar 11, 2034
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to learn more about an investigational medicine called PF-08634404 when used alone or in combination with other anti-cancer medicines in adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has spread beyond the lung. PF-08634404 is designed to target two pathways involved in cancer growth and survival. The study will also evaluate combinations with chemotherapy and tarlatamab, an approved immunotherapy that helps the body's immune system recognize and attack small cell lung cancer cells. To join the study, participants must meet the following conditions: * 18 years of age or older. * Have extensive-stage small cell lung cancer confirmed by laboratory testing. * Have measurable disease on imaging scans. * Be in generally good physical condition and have adequate organ function. * For most study groups, have not received prior systemic treatment for extensive-stage small cell lung cancer, although participants who received a single cycle of chemotherapy for life-threatening disease-related symptoms are eligible. The study has two parts: Phase 2 Researchers will evaluate the safety, tolerability, and preliminary anti-cancer activity of PF-08634404. Participants may receive: * PF-08634404 plus chemotherapy, * PF-08634404 plus tarlatamab, or * PF-08634404 plus tarlatamab and chemotherapy. The results will help determine the recommended dose and treatment regimen for future study. Phase 3 Researchers will compare PF-08634404 plus chemotherapy with an approved treatment regimen consisting of atezolizumab plus chemotherapy. The goal is to determine whether PF-08634404 can improve outcomes such as overall survival.
Conditions
- Small Cell Lung Cancer (SCLC)
Interventions
PF-08634404Drug
Concentrate for solution for infusion
TarlatamabDrug
Lyophilized powder intended for reconstitution and dilution for intravenous use
ChemotherapyDrug
Injection for intravenous use
AtezolizumabDrug
Injection for intravenous use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2: Number of participants with treatment-emergent adverse eventsTime frame: Up to 90 days after the last dose of treatment
- Phase 3: Overall Survival (OS)Time frame: Up to approximately 2 years after completion of study treatment of last study participant
Locations
85 sites in 10 countries. Site status is shown where the registry gives one.
Highlands Oncology Group
Fayetteville, Arkansas · Recruiting
Highlands Oncology Group
Rogers, Arkansas · Recruiting
Highlands Oncology Group
Springdale, Arkansas · Recruiting
BRCR Coral Springs
Coral Springs, Florida · Recruiting
BRCR Global - Coral Springs
Coral Springs, Florida · Recruiting
Mid Florida Hematology and Oncology Center
Orange City, Florida · Recruiting
BRCR Global - Tamarac
Tamarac, Florida · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
Texas Oncology - Northeast Texas
Allen, Texas · Recruiting
Texas Oncology - DFW
Arlington, Texas · Recruiting
Texas Oncology - DFW
Arlington, Texas · Recruiting
Texas Oncology - Gulf Coast
Beaumont, Texas · Recruiting
Texas Oncology - DFW
Bedford, Texas · Recruiting
Texas Oncology - DFW
Dallas, Texas · Recruiting
Texas Oncology - DFW
Dallas, Texas · Recruiting
Texas Oncology - DFW
Dallas, Texas · Recruiting
Texas Oncology - DFW
Dallas, Texas · Recruiting
Texas Oncology - DFW
Dallas, Texas · Recruiting
Texas Oncology - Northeast Texas
Denison, Texas · Recruiting
Texas Oncology - Northeast Texas
Denton, Texas · Recruiting
Texas Oncology - Northeast Texas
Flower Mound, Texas · Recruiting
Texas Oncology - DFW
Fort Worth, Texas · Recruiting
Texas Oncology - San Antonio
Fredericksburg, Texas · Recruiting
Texas Oncology - DFW
Grapevine, Texas · Recruiting
Texas Oncology - Gulf Coast
Houston, Texas · Recruiting
Texas Oncology - Gulf Coast
Houston, Texas · Recruiting
US Oncology Investigational Product Center (IPC)
Irving, Texas · Recruiting
US Oncology Investigational Products Center (IPC)
Irving, Texas · Recruiting
Texas Oncology - Northeast Texas
Lewisville, Texas · Recruiting
Texas Oncology - Northeast Texas
Longview, Texas · Recruiting
Texas Oncology - Northeast Texas
McKinney, Texas · Recruiting
Texas Oncology - San Antonio
New Braunfels, Texas · Recruiting
Texas Oncology - Northeast Texas
Palestine, Texas · Recruiting
Texas Oncology - Northeast Texas
Paris, Texas · Recruiting
Texas Oncology - Gulf Coast
Pearland, Texas · Recruiting
Texas Oncology - DFW
Plano, Texas · Recruiting
Texas Oncology - DFW
Plano, Texas · Recruiting
Texas Oncology - San Antonio
San Antonio, Texas · Recruiting
Texas Oncology - San Antonio
San Antonio, Texas · Recruiting
Texas Oncology - San Antonio
San Antonio, Texas · Recruiting
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.